# US 2014/0194521 A1 · Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194521 A1 - Document ID: US20140194521A1 - Status: Published application - Kind: A1 - Application number: 14/101,234 - Filed: 2013-12-09 - Published: 2014-07-10 - Earliest claimed: 2001-11-23 - Assignees: Protistia Biotechnology AB - Applicants: Protistia Biotechnology AB - Inventors: Tadeusz STUDZINSKI; Jose Luis VALVERDE PIEDRA; Stefan PIERZYNOWSKI - Web page: https://patentgrep.com/patent/US20140194521A1 ## CPC - A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid - A23L 33/175: Amino acids - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61P 19/00: Drugs for skeletal disorders - A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease - A61P 19/10: for osteoporosis - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION ## Abstract A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment. ## Claims ### Claim at position 1 1-30. (canceled) ### Claim 31 A method of reducing the risk of or treating osteoporosis, the method comprising administering a member selected from alpha-ketoglutaric acid (AKG) and a pharmaceutically acceptable salt thereof, to a vertebrate in need thereof. ### Claim 32 (depends on 31) The method according to claim 31, comprising administering a composition comprising the member and a pharmaceutically acceptable carrier and/or additives to the vertebrate. ### Claim 33 (depends on 32) The method according to claim 32, wherein the composition is a food or a feed supplement. ### Claim 34 (depends on 32) The method according to claim 32 wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage. ### Claim 35 (depends on 31) The method according to claim 31, comprising administering a therapeutically effective amount of the member to the vertebrate. ### Claim 36 (depends on 35) The method according to claim 35, wherein the therapeutically effective amount is 0.01-0.2 g/kg bodyweight per daily dose. ### Claim 37 A method of improving bone quality in a vertebrate, including a mammal and a bird, comprising administering a member selected from the group consisting of alpha-ketoglutaric acid (AKG) and a pharmaceutically acceptable salt thereof, to a vertebrate in the need thereof. ### Claim 38 (depends on 37) The method according to claim 37, comprising administering a composition comprising the member and a pharmaceutically acceptable carrier and/or additives to the vertebrate. ### Claim 39 (depends on 38) The method according to claim 38, wherein the composition is a food or a feed supplement. ### Claim 40 (depends on 38) The method according to claim 38, wherein the composition is a dietary supplement and/or a component in form of solid food and/or beverage. ### Claim 41 (depends on 37) The method according to claim 37, comprising administering a therapeutically effective amount of the member to the vertebrate. ### Claim 42 (depends on 41) The method according to claim 41, wherein the therapeutically effective amount is 0.01-0.2 g/kg bodyweight per daily dose. ### Claim 43 (depends on 31) The method according to claim 31, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 44 (depends on 31) The method according to claim 31, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 45 (depends on 32) The method according to claim 32, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 46 (depends on 32) The method according to claim 32, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 47 (depends on 35) The method according to claim 35, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 48 (depends on 35) The method according to claim 35, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 49 (depends on 37) The method according to claim 37, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 50 (depends on 37) The method according to claim 37, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 51 (depends on 38) The method according to claim 38, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 52 (depends on 38) The method according to claim 38, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered ### Claim 53 (depends on 41) The method according to claim 41, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 54 (depends on 41) The method according to claim 41, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 55 (depends on 31) The method according to claim 31, wherein the vertebrate is affected with osteoporosis. ### Claim 56 (depends on 31) The method according to claim 31, wherein the vertebrate is not affected with osteoporosis. ### Claim 57 A method of treating osteopenia and preventing osteoporosis, the method comprising administering a member selected from alpha-ketoglutaric acid (AKG) and a pharmaceutically acceptable salt thereof, to a vertebrate in need thereof. ### Claim 58 (depends on 57) The method according to claim 57, comprising administering a composition comprising the member and a pharmaceutically acceptable carrier and/or additives to the vertebrate. ### Claim 59 (depends on 58) The method according to claim 58, wherein the composition is a food or a feed supplement. ### Claim 60 (depends on 58) The method according to claim 58, wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage. ### Claim 61 (depends on 57) The method according to claim 57, comprising administering a therapeutically effective amount of the member to the vertebrate. ### Claim 62 (depends on 61) The method according to claim 61, wherein the therapeutically effective amount is 0.01-0.2 g/kg bodyweight per daily dose. ### Claim 63 (depends on 57) The method according to claim 57, wherein a pharmaceutically acceptable mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered. ### Claim 64 (depends on 57) The method according to claim 57, wherein a pharmaceutically acceptable amino-acid salt of alpha-ketoglutaric acid (AKG) is administered.